First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Autor: Alessandro D. Santin, George R. Blumenschein, Raffit Hassan, Johanna C. Bendell, John Nemunaitis, Dirk Laurent, Nenad Sarapa, Annette O. Walter, Stella K. Kim, Shelly Seward, Barrett H. Childs, Kathleen N. Moore, Anish Thomas, Cem Elbi, Hedy L. Kindler, Prabhu Rajagopalan

Publikováno v: Journal of Clinical Oncology

PURPOSE This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody–drug conjugate of anti-mesothelin antibo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c6a9246f60875f9ed7bf5d6a9c85ab9
https://pubmed.ncbi.nlm.nih.gov/32213105

Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer

Autor: Ismail Mert, Shailendra Giri, Marta Llauradó, Jing Dai, Shelly Seward, Ramandeep Rattan, Jasdeep Chhina, Ghassan Allo, Mark S. Carey, Adnan R. Munkarah

Publikováno v: Gynecologic Oncology. 146:319-326

Objective Low-grade serous ovarian cancer (LGSOC) constitutes 5–8% of epithelial ovarian cancers and is refractory to chemotherapy. We and others have shown metformin to cause significant growth inhibition in high-grade ovarian cancer both in vitro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc5de4aa8c76d2b8b6b56c400f07ece
https://doi.org/10.1016/j.ygyno.2017.05.019

EZH2-shRNA–mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma

Autor: Shelly Seward, Sreedhar Chamala, David L. Bouwman, Assaad Semaan, Donald W. Weaver, Aamer Qazi, Ramesh B. Batchu, Scott A. Gruber, Oksana V. Gruzdyn, Vasu B. Dhulipala

Publikováno v: Surgery. 154:739-747

Purpose Enhancer of zeste homologue 2 (EZH2), a component of the chromatin modification protein complex, is upregulated in pancreatic ductal adenocarcinoma (PDAC), whereas loss of p53 and its downstream target, p21 waf1/cip1 , is also observed freque

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5e244d0adab1157c4604a77bb29ede
https://doi.org/10.1016/j.surg.2013.06.041

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis

Autor: Shelly Seward, David H. Moore, Junzo Chino, Ritu Salani, David Miller, Rachelle Lanciano, J. Tate Thigpen, Paul DiSilvestro, Krishnansu S. Tewari, Peter G. Rose, Frederick B. Stehman, Kathleen N. Moore, James J. Java, Katrina N. Slaughter, Yi-Chun Lee

Publikováno v: Moore, KN; Java, JJ; Slaughter, KN; Rose, PG; Lanciano, R; DiSilvestro, PA; et al.(2016). Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. GYNECOLOGIC ONCOLOGY, 143(2), 294-301. doi: 10.1016/j.ygyno.2016.08.317. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/22m133p7
BASE-Bielefeld Academic Search Engine

Objective To determine the effect of age on completion of and toxicities following treatment of local regionally advanced cervical cancer (LACC) on Gynecologic Oncology Group (GOG) Phase I-III trials. Methods An ancillary data analysis of GOG protoco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9281c85b1f3c53ef96c893db15c3b106
http://www.escholarship.org/uc/item/22m133p7

Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: An epidemiological analysis

Autor: Agnieszka Vay, Adnan R. Munkarah, Assaad Semaan, Sanjeev Kumar, Charles A. Schiffer, Robert T. Morris, Shelly Seward

Publikováno v: Gynecologic Oncology. 123:456-460

Therapy related acute myeloid leukemia (t-AML) is a potential late complication of cytotoxic therapy, and it is of particular concern in the treatment of patients with epithelial ovarian carcinoma (EOC) exposed to multiple courses of chemotherapy dur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e0a736da963302c774dea4f74d3a03f
https://doi.org/10.1016/j.ygyno.2011.07.097